Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$1.40
+0.7%
$1.44
$0.99
$5.77
$88.33M2.2788,212 shs248,489 shs
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$2.85
-0.7%
$4.04
$2.28
$6.71
$361.53M1.851.18 million shs814,703 shs
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$3.65
$3.65
$2.30
$6.65
$381.02M0.93.36 million shsN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
$7.88
-0.1%
$2.67
$1.31
$7.95
$367.78M1.9652,735 shs849,129 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MacroGenics, Inc. stock logo
MGNX
MacroGenics
+0.72%-11.39%-12.50%-43.09%-66.18%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
-0.70%-4.04%-41.60%-54.19%+10.89%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00%0.00%0.00%0.00%+30.36%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-0.13%0.00%+310.42%+225.62%+165.32%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
MacroGenics, Inc. stock logo
MGNX
MacroGenics
3.8018 of 5 stars
3.21.00.04.42.72.50.6
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
4.0483 of 5 stars
3.31.00.04.33.23.30.6
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.3123 of 5 stars
3.10.00.04.71.41.70.6
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
3.1369 of 5 stars
4.03.00.00.02.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MacroGenics, Inc. stock logo
MGNX
MacroGenics
2.40
Hold$5.71308.16% Upside
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
2.50
Moderate Buy$5.5092.98% Upside
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.13
Hold$8.45131.51% Upside
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
2.00
Hold$10.8037.06% Upside

Current Analyst Ratings Breakdown

Latest MGNX, RVNC, VIGL, and ORGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$11.00 ➝ $8.00
5/27/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$14.00 ➝ $8.00
5/23/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Neutral$8.00
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$13.00 ➝ $8.00
5/20/2025
MacroGenics, Inc. stock logo
MGNX
MacroGenics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$152.43M0.58N/AN/A$2.46 per share0.57
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$458.76M0.79$0.18 per share15.72$2.11 per share1.35
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$234.04M1.63N/AN/A($1.73) per share-2.11
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/A$3.24 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$9.06M-$0.89N/AN/AN/A-69.07%-89.42%-38.57%8/5/2025 (Estimated)
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$4.95M-$0.17N/AN/AN/A-1.62%-2.69%-1.63%8/14/2025 (Estimated)
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$82.64M-$2.05N/AN/AN/AN/A-83.89%-65.34%8/12/2025 (Estimated)

Latest MGNX, RVNC, VIGL, and ORGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.61-$0.65-$0.04-$0.65$9.59 million$13.19 million
5/8/2025Q1 2025
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/7/2025Q1 2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$0.53-$0.49+$0.04-$0.49N/AN/A
3/20/2025Q4 2024
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.23-$0.25-$0.02-$0.25$34.17 million$49.40 million
3/13/2025Q4 2024
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$0.49-$0.57-$0.08-$0.57N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/AN/AN/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/AN/AN/AN/AN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/A
3.75
3.69
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
0.21
3.09
2.74
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/A
4.12
3.05
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/A
3.72
3.72

Institutional Ownership

CompanyInstitutional Ownership
MacroGenics, Inc. stock logo
MGNX
MacroGenics
96.89%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
49.57%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
97.70%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
83.64%

Insider Ownership

CompanyInsider Ownership
MacroGenics, Inc. stock logo
MGNX
MacroGenics
13.00%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
33.00%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
5.10%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
18.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
MacroGenics, Inc. stock logo
MGNX
MacroGenics
43063.09 million55.67 millionOptionable
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
950126.85 million79.33 millionOptionable
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
500104.39 million99.07 millionOptionable
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
4046.67 million27.38 millionNot Optionable

Recent News About These Companies

Stifel Downgrades Vigil Neuroscience (VIGL)
Q2 EPS Estimate for Vigil Neuroscience Boosted by Analyst
Mizuho Downgrades Vigil Neuroscience (NASDAQ:VIGL) to Hold
Vigil Neuroscience (NASDAQ:VIGL) Cut to "Hold" at Wedbush

New MarketBeat Followers Over Time

Media Sentiment Over Time

MacroGenics stock logo

MacroGenics NASDAQ:MGNX

$1.40 +0.01 (+0.72%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$1.44 +0.05 (+3.21%)
As of 05/29/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$2.85 -0.02 (-0.70%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$2.95 +0.10 (+3.51%)
As of 05/29/2025 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Revance Therapeutics stock logo

Revance Therapeutics NASDAQ:RVNC

$3.65 0.00 (0.00%)
As of 02/6/2025

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Vigil Neuroscience stock logo

Vigil Neuroscience NASDAQ:VIGL

$7.88 -0.01 (-0.13%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$7.86 -0.01 (-0.19%)
As of 05/29/2025 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.